DN-2024001

DN-2024001 is an investigational small molecule therapeutic candidate being developed by the South Korean pharmaceutical company Daehan Nupharm for the treatment of hyperlipidemia. Currently in the early stages of development, specifically within the formulation research phase of the company's R&D pipeline, the drug is intended to manage abnormal lipid levels, such as elevated cholesterol or triglycerides. These lipid disorders are significant risk factors for atherosclerosis and cardiovascular disease. While the specific biological target (such as HMG-CoA reductase or NPC1L1) has not been publicly disclosed, the project represents Daehan Nupharm's strategic effort to expand its cardiovascular and metabolic disease portfolio. The drug is being developed as a pharmaceutical intervention to provide new therapeutic options for patients requiring lipid-lowering therapy.